Cratered by Kratom

Kratom is an increasingly popular drug of abuse and readily available on the “recreational” drug market. Between 3 million and 5 million people in the U.S. use kratom, and reported poisonings from people taking it have soared.

The U.S. Food and Drug Administration (FDA) has warned against using Mitragyna Speciosa, commonly known as kratom, a tree in the coffee family which grows naturally in Thailand, Malaysia, Indonesia, Philippines, Vietnam, Myanmar, and Papua New Guinea. The concern is that kratom leaves, which affect the same opioid brain receptors as morphine, appear to have properties that expose users to the risks of addiction, abuse, and dependence.

There are no FDA-approved uses for kratom because there is no scientific evidence to support its medical use, and the FDA urges consumers to report any adverse reactions to the FDA’s MedWatch program.

The race is on to get patents for synthetics and derivatives of Mitragyna Speciosa. Doctors and mental health workers need to be aware of the psychopathological effects of these substances.

Because kratom is still legal in the U.S., it has become a go-to drug for individuals with chronic pain, promoted anecdotally by some psychiatrists both to mitigate pain and to ease withdrawal from other opioids.

Some other psychiatrists are convinced of kratom’s mental health benefits as a potential therapeutic agent.

Here again we see psychiatry, with its long history of harmful drug pushing, justifying and promoting the latest in a long line of such harmful, addictive and psychedelic drugs.

Similar to the dose-dependent characteristics of any drug, in relatively small amounts kratom acts as a stimulant; in relatively larger amounts it causes sedation; and when overdosed it can cause death.

Kratom’s psychoactive compounds, mitragynine and 7-hydroxymitragynine, are opioid-receptor agonists, which means they are chemicals that bind to the same receptors in the brain to which opioids bind, thus acting in the brain similar to other opioids like morphine and codeine.

Side effects of taking (or withdrawing from) kratom may include dependence, nausea, vomiting, aggression, hallucinations, delusions, psychosis, seizures, thyroid problems, increased risk of suicide, trouble breathing, brain swelling, seizures, liver damage, or death.

In spite of the American Kratom Association’s lobbying efforts to promote this harmful substance, and its repeated references to the American Psychiatric Association for support, we find that there is sufficient reason to be highly skeptical.

Click here for more information about kratom.

Psychiatric Inpatients Have Elevated Risks for Adverse Reactions

[Reference: “Multiple adverse outcomes following first discharge from inpatient psychiatric care: a national cohort study”, The Lancet Psychiatry, June 03, 2019]

People discharged from inpatient psychiatric care are at higher risk than the rest of the population for a range of serious fatal and non-fatal adverse outcomes.

These individuals are also more likely to perpetrate violent crimes, including homicide. Suicide risk is known to be especially raised soon after discharge.

Results were summarized from 62,922 Danish people who had been discharged from inpatient psychiatric services and 1,573,050 who had never been a psychiatric inpatient, examining these adverse outcomes over ten years post-discharge: mortality, suicide, accidental death, homicide victimization, homicide perpetration, non-fatal self-harm, violent criminality, and hospitalization following violence.

The risk of at least one of these adverse outcomes was highest in people using psychoactive drugs.

Although no detailed clinical information was available regarding what psychiatric treatments were given, it can be assumed that psychiatric (psychoactive) drugs were a major part of most treatments, since worldwide statistics show that a rapidly increasing percentage of every age group, from children to the elderly, rely heavily and routinely on psychiatric drugs in their daily lives. Worldwide sales of antidepressants, for example, were more than $14 billion in 2017, and expected to surpass $15 billion by 2023.

These statistics give one more result in a long line of significant research that concludes:

  • psychiatry cannot cure any so-called mental illness
  • psychiatric treatments cause violence and suicide
  • psychiatric treatments actually harm rather than help vulnerable people
  • psychiatry is junk science
  • psychiatric drugs can only chemically mask problems and symptoms; they cannot and never will be able to solve problems

People in desperate circumstances must be provided proper and effective medical care. Medical, not psychiatric, attention, good nutrition, a healthy, safe environment and activity that promotes confidence will do far more than the brutality of psychiatry’s treatments.

While life is full of problems, and sometimes those problems can be overwhelming, it is important for you to know that psychiatry, its diagnoses and its drugs are the wrong way to go.

Mental Health in St. Louis

A new report (“St. Louis Regional Mental Health Data Report“, May, 2019) outlines mental health trends in the St. Louis, Missouri region.

The St. Louis County Department of Public Health and the City of St. Louis Department of Health prepared the report for System of Care St. Louis Region.

One significant finding is that “…intentional self-harm (i.e., suicide) was the sixth leading cause of death for children under 18 years of age and the third leading cause of death for ages 18 to 24 years in St. Louis County, and it is the tenth leading cause of death for all age groups in both the United States and the state of Missouri.”

Unfortunately, the report fails to notice that there is overwhelming evidence that psychiatric drugs cause suicide and violence.

While there is never one simple explanation for what drives a human being to commit such unspeakable acts of violence, all too often one common denominator has surfaced in hundreds of cases—-prescribed psychiatric drugs which are documented to cause mania, psychosis, violence, suicide and in some cases, homicidal ideation. To date, there has been no federal investigation of the link between psychiatric drugs and acts of suicide and violence.

Mental disorder is not a predictor of aggressive behavior, but rather the adverse effects of the drugs prescribed to treat it. Drug proponents argue that there are many shootings and acts of violence that have not been correlated to psychiatric (psychotropic) drugs, but that is exactly the point. It has neither been confirmed nor refuted, as law enforcement is not required to investigate or report on prescribed drugs linked to suicide and violence, and media rarely pose the question.

Those with a vested, financial interest will continue to champion the use of such drugs, as the psychiatric-pharmaceutical drug industry rakes in an average of $35 billion a year in sales in the U.S. alone. It is that vested financial interest which may be preventing a thorough investigation of the link between prescription psychoactive drugs and increased suicide and violence, especially considering that there have been calls for such investigations since the Columbine High School massacre in 1999.

The theory that a person is violent because he “stopped taking his medication” is misleading and omits the fact that it is more likely to be the withdrawal from a drug of dependence that is experienced—-not the return of the person’s “untreated mental illness.” Numerous studies and expert opinions support this. Psychotropic drug withdrawal destroys mental faculties and creates impulsivity.

It is long past time that government agencies answered that call with an investigation. Legislative hearings should be held to fully investigate the correlation between psychiatric treatment and violence and suicide. None can argue against the fact that disclosure of the facts would serve the public interest.

Click here for more information about the link between suicide, violence, and psychiatric drugs.

You’re Not Paranoid, It’s Really Happening

Abilify Mycite® (aripiprazole tablets with sensor, from Otsuka Pharmaceutical) is a prescription drug of an aripiprazole tablet (an atypical antipsychotic) with a metallic Ingestible Event Marker (IEM) sensor inside it, used in adults for diagnoses of schizophrenia, bipolar I disorder, and major depressive disorder. A month’s supply of it costs around $1,650. The actual mechanism of action of aripiprazole is unknown, although it messes with the levels of dopamine and serotonin in the brain, which is playing Russian Roulette with your mind.

The sensor is intended to track, with a smartphone app, if the drug has been taken. The ability of this drug to improve patient compliance or modify dosage has not been established. The only thing the FDA approved was functions related to tracking drug ingestion. The use of this drug to track drug ingestion in real-time or during an emergency is not recommended because detection may be delayed or not occur.

The drug sends information to a patch worn on the patient’s arm, which is then logged on a mobile app, which then sends the data to their doctor. Some experts warn that the idea of swallowing a tracking chip may be too much for paranoid patients to handle.

Said one expert, “I am concerned about the formation of new pharmaceutical persons who are digitally enhanced to be compliant with the profit motives of corporations and the directives of health providers and drug companies. … The fact that the drug is Abilify, which is prescribed to people who experience serious mental distress, should raise many ethical red flags. These concerns are especially relevant because the patent for the original Abilify drug expired in 2016… My concern is that … the company will be motivated to profit from the technology as much as possible, regardless of whether the drug actually improves health.”

The idea for this gross invasion of privacy comes about because refusing to take prescribed drugs is a particular psychiatric concern, and is even enshrined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as “Nonadherence to medical treatment.”

Abilify MyCite is still not widely used in the US, possibly because of skepticism from patients, prescribing doctors and insurance providers, although Otsuka has collaborated with Magellan Health to roll the drug out to the US, and UnitedHealthcare has developed complex rules for insurance authorization.

This drug has potentially severe side effects including stroke; akathisia; neuroleptic malignant syndrome; tardive dyskinesia; unusual urges such as compulsive gambling, sex, eating, or shopping; seizures; suicidal thoughts or behaviors. Side effects may be considerably more severe with known CYP2D6 poor metabolizers (a Cytochrome P450 enzyme.)

This drug also has a Boxed Warning about an increased risk of suicidal thinking and behavior in children, adolescents and young adults.

Recognize that the real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax — unscientific, fraudulent and harmful.

If you are taking this drug, do not stop suddenly. You could suffer serious withdrawal symptoms. You should seek the advice and help of a competent medical doctor or practitioner before trying to come off any psychiatric drug.

Chanting the Chantix Mantra

Recently there has been a gross increase in the TV ad campaign for Chantix, promoting this deadly drug for smoking cessation.

We’ve written about Chantix before, but we thought a repeat was in order due to this massive ad campaign.

In 2008 the Federal Aviation Administration banned Chantix for pilots and air traffic controllers, and reissued that decision in 2013.

The U.S. Food and Drug Administration (FDA) slapped a “Black Box” warning on Chantix (varenicline tartrate, made by Pfizer) in 2009 after receiving thousands of reports linking the drug to mental health issues, including suicidal thoughts, hostility and agitation.

In 2015, the FDA expanded the warning to note that the drug had also been linked to reduced alcohol tolerance leading to seizures.

However, in 2016 the FDA removed the Black Box warning, after heavy lobbying from Pfizer claiming that additional data showed that the benefits of Chantix outweighed its adverse side effects (oh, and since its sales had significantly dropped.)

But the adverse side effects did not go away; only the Black Box warning went away. One study found that Chantix had more cases of suicidal thoughts, self-harm, and homicidal thoughts than any other drug, by a more than three-fold margin. Pfizer’s prescribing information still warns about new or worsening mental health problems such as changes in behavior or thinking, aggression, hostility, agitation, depressed mood, or suicidal thoughts or actions while taking or after stopping Chantix.

We suspect that the recent spate of TV ads is related to the removal of the Black Box warning and the prior drop in sales. Also, the price of Chantix more than doubled between 2013 and 2018. In 2013, Pfizer paid out $273 million to settle a majority of the 2,700 state and federal lawsuits that had been filed over adverse side effects. Now the company is trying to grow the market with clinical studies for smokers age 12 to 19.

What is Chantix?

Chantix is a psychiatric drug — a benzodiazepine-based anti-anxiety drug, also called a minor tranquilizer or sedative hypnotic. Daily use of therapeutic doses of benzodiazepines are associated with physical dependence, and addiction can occur after 14 days of regular use. Typical consequences of withdrawal are anxiety, depression, sweating, cramps, nausea, psychotic reactions and seizures. There is also a “rebound effect” where the individual experiences even worse symptoms than they started with as a result of chemical dependency.

The exact mechanism of action of benzodiazepines is not known, but they affect neurotransmitters in the brain and suppress the activity of nerves, under the unproven theory that excessive activity of nerves may be the cause of anxiety. Chantix was developed to specifically affect nicotinic receptors in the brain, under the theory that this would reduce nicotine craving and block the rewarding effects of smoking. Messing with neurotransmitters in the brain is playing Russian Roulette with your mind.

Benzodiazepines are metabolized by cytochrome P450 enzymes, so a genetic lack of these enzymes can cause a buildup of harmful toxins and increase the severity of adverse side effects.

Psychiatric “best practices” consider that smoking is an addiction and recommend that psychiatrists assess tobacco use at every patient visit, since tobacco addiction is covered in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a “mental illness” under eight separate items, and disorders related to inhalant use have 33 entries. Smoking is not a mental illness and addiction cannot be fixed with psychiatric drugs.

The psychiatric industry considers that smoking cessation therapies are their territory, however this drug masks the real cause of problems in life and debilitates the individual, thus denying one the opportunity for real recovery and hope for the future. Treating substance abuse with drugs is a major policy blunder; contact your state and federal representatives and let them know you disapprove of this trend.

Recognize that the real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior like smoking as a “disease.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax — unscientific, fraudulent and harmful. All psychiatric treatments, not just psychiatric drugs, are dangerous.

Hear This — Zone Out on Zonisamide

The March 15-21, 2019 issue of the St. Louis Business Journal noted a $10.5 million Army grant to the Washington University in St. Louis Medical School to study the epilepsy drug Zonisamide to see if it could prevent hearing loss from loud noises. This seemed like such an imaginative stretch that we decided to look into it in more detail.

The justification given is that Zonisamide is conjectured to protect hearing loss when given ahead of exposure to loud noises. We wondered how this came about. We also note that other epilepsy drugs are psych-related, so we wondered if there was a psych drug connection here as well.

In a rat study, researchers proposed using a substance that blocks calcium channels to see if it could prevent hearing loss against loud noises. Zonisamide also blocks calcium channels. Gee, maybe Zonisamide can prevent hearing loss.

Zonisamide is the generic name used in the United States for a seizure drug whose common brand name is Zonegran. It was first used in Japan in the early 1970’s to treat so-called psychiatric disorders, and has been used off-label by psychiatrists in the U.S. as a mood stabilizer. The FDA approved it for seizures in 2000, although it is totally unknown as to how it works to prevent seizures. The FDA notes that taking this drug may increase the risk of depression, psychosis and suicidal thoughts or actions.

Using Zonisamide during pregnancy may present a significant risk to the fetus due to the possibility of birth defects.

Zonisamide was first studied in Japan in the 1970’s during exploratory research on drugs for psychiatric disorders. The drug alters the concentration of dopamine in the brain, but is apparently dosage dependent — that is, different dosages can increase or decrease dopamine concentrations, leading to unpredictable results.

Zonisamide is metabolized in the liver by Cytochrome P450 enzymes, so its side effects can be magnified in those persons with a genetic lack of these enzymes.

Typically we see that the psychiatric research community makes a guess about re-purposing some old drug so it can be re-used for a new patient population, guesses how it might work in the rat brain, then guesses how it might work in the human brain, each time asking for more funding to make further guesses, eventually leading to the FDA approving a new use for an old drug even though they still don’t know how it “works.”

While medicine has advanced on a scientific path to major discoveries and cures, psychiatry has never evolved scientifically and is no closer to understanding or curing mental problems, thus must continually seek to find new uses for old treatments.

While medicine has nurtured an enviable record of achievements and general popular acceptance, the public still links psychiatry to snake pits, straitjackets, and “One Flew Over the Cuckoo’s Nest.” Psychiatry continues to foster that valid impression with its development of such brutal treatments as ECT, psychosurgery, the chemical straitjacket caused by antipsychotic drugs, and its long record of treatment failures including Zonisamide as a mood stabilizer.

In over 40 years, “biological psychiatry” has yet to validate a single psychiatric condition/diagnosis as an abnormality/disease, or as anything neurological, biological, chemically imbalanced or genetic.

The drugs prescribed for psychiatric conditions, such as using Zonisamide as a mood stabilizer, only exacerbate the conditions they are supposed to treat. And when these drugs are used for other non-psychiatric conditions, they continue having the same adverse reactions, such as depression and suicide when Zonisamide is used for epilepsy. It will have the same adverse reactions if it is ever used for hearing loss. And they will still not know how it “works.”

We suggest that funding only be provided for workable medical treatments that dramatically improve and cure health and mental health problems. For more information, download and read the CCHR booklet “Psychiatric Hoax – The Subversion of Medicine – Report and recommendations on psychiatry’s destructive impact on health care.

Knock Yourself Out with Spravato (Esketamine)

A nasal spray version of the anesthetic drug ketamine was approved by the FDA on March 5, 2019 for treatment-resistant depression.

Janssen Pharmaceuticals says that the cost for a one-month course of treatment for Spravato (generic esketamine) will be between $4,720 and $6,785.

Esketamine is the S-enantiomer of ketamine, which means that it is one of the two mirror images of the chemical structure of ketamine, S (for the Latin sinister) being the left image. It enhances glutamine release in the brain. Glutamine is an amino acid used in the synthesis of proteins, among other things. In the brain, glutamine is used in the production of neurotransmitters. It is believed that glutamine plays a role in raising or lowering aggression levels.

Treatment requires that doses be taken, in conjunction with an oral antidepressant, in a doctor’s office or clinic, with patients monitored for at least two hours, and their experience entered in a registry.

Because of the risk of serious adverse outcomes and the potential for abuse and misuse of the drug, it is only available through a restricted distribution system. At least you can’t take it home with you.

The Spravato labeling contains a Boxed Warning that cautions that patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug.

Basically, it knocks you out so you don’t feel so depressed anymore. You don’t feel much of anything, actually, since you’ve just taken an anesthetic in the snout.

There were four phase 3 clinical trials; two of them failed to show any statistical improvement, but the drug was approved anyway because it was on the Fast Track and Breakthrough Therapy paths.

A 9/5/2018 update from Consumer Reports said, “All these drugs [Ketamine, Phenylbutazone, Chloramphenicol] are prohibited in beef, poultry, and pork consumed in the U.S. Yet government data obtained by Consumer Reports suggest that trace amounts of these and other banned or severely restricted drugs may appear in the U.S. meat supply more often than was previously known.”

Note that “depression” is not an actual medical illness; it is simply a symptom of some undiagnosed and untreated condition. A diagnosis of depression is a prime example of psychiatric fraud.

Any form of ketamine used to treat so-called depression is unethical and harmful, since it precludes the patient from finding out what is actually wrong and getting that treated. Psychiatrists pushing ketamine or esketamine are shameful drug pushers who are making a buck off people’s misfortune.

Go here for more information about alternatives to drugs.

Orilissa May Cause Suicidal Ideation

Orilissa (generic elagolix) is a drug from AbbVie Inc. and Neurocrine Biosciences, approved by the FDA in the summer of 2018, and prescribed for women with moderate to severe endometriosis pain. Endometriosis is a chronic disease in which uterine lining tissue grows outside the uterus. The drug shuts down the hormonal cycle, stopping the monthly menstrual period. It is currently being heavily advertised, with a list price of approximately $850 per month.

It caught our attention because some of the serious side effects are suicidal thoughts, actions, or behavior, and worsening of mood.

The prescribing information advises that patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional. We urge caution, because a psychiatrist may misdiagnose such symptoms as a mental disorder rather than a drug side effect, and prescribe harmful psychotropic drugs instead of properly handling the side effects.

Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with Orilissa in the endometriosis clinical trials. Users had a higher incidence of depression and mood changes compared to placebo. Some of the most common adverse reactions in clinical trials included anxiety, depression and mood changes.

The drug is a gonadotropin-releasing hormone antagonist, which means it blocks the receptors of certain hormones in the brain’s pituitary gland, leading to the suppression of luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone. Patients are advised to limit the duration of use because of bone loss; bone mineral density loss is greater with increasing duration of use and may not be completely reversible.

The drug is metabolized in the liver by cytochrome P450 enzymes, so a person genetically deficient in these enzymes, or who is taking other drugs that inhibit CYP450 enzymes, is at risk of a toxic accumulation of the drug leading to more severe side effects.

There does not appear to be any scientific data about exactly why suicidality and behavior changes are potential adverse reactions, but we might surmise that messing with hormones in the brain is not exactly a well-known precision science.

The major issue we see is that mood changes as a side effect from Orilissa are likely to be misdiagnosed. Since psychiatrists do not perform clinical tests and are wont to prescribe an antidepressant rather than get to the root of the problem, we want to be sure every candidate for this drug understands the issue and practices full informed consent to any psychiatric treatment.

Missouri child psychiatry project got federal grant

In November 2018, the St. Louis Business Journal wrote, “The Missouri Department of Mental Health was awarded a $425,000 federal grant to fund expansion of a state project to expand access to mental health care for children.”

“The Health Resources and Services Administration recently awarded $7.9 million combined to 18 states to integrate behavioral health into pediatric primary care.”

This effort targets young children by integrating the efforts of physicians, nurse practitioners, behavioral health clinicians, community health workers, home visitors, and other health care providers to funnel children into the mental health care system.

The Child Psychiatry Access Project in Missouri provides child psychiatry phone consultation to primary care providers in several counties, with a goal of providing these services statewide by October 2020.

The U.S. Health Resources and Services Administration of the Department of Health & Human Services says, “State or regional networks of pediatric mental health teams will provide tele-consultation, training, technical assistance and care coordination for pediatric primary care providers to diagnose, treat and refer children with behavioral health conditions.”

Participating agencies are: University of Missouri School of Medicine, Behavioral Health Network, Assessment Resource Center, Behavioral Health Response, Washington University Pediatric and Adolescent Ambulatory Research Consortium, and the National Alliance for Mental Illness.

Why Do We Think This Is Bad?

No one denies that proper mental health care for children is a good thing. Unfortunately, the current state of mental health care for children is mostly prescribing them harmful and addictive psychotropic drugs for fraudulent “mental illnesses.”

They assert that up to 25% of children need this behavioral health care, which is patently false.

Health care providers do not require informed consent from the family to call and discuss a case with these behavioral health consultants.

The trouble is that psychiatric propaganda on the subject of children has thoroughly duped well-meaning parents, teachers and politicians alike, that “normal” childhood behavior is no longer normal; that it is a mental illness. And further, that only by continuous, heavy drugging from a very early age, can the “afflicted” child possibly make it through life’s worst.

Contrary to psychiatric opinion, children are not “experimental animals,” they are human beings who have every right to expect protection, care, love and the chance to reach their full potential in life. They will only be denied this from within the verbal and chemical straitjackets that are psychiatry’s labels and drugs.

Through massive promotion and marketing campaigns, psychiatric drugs are increasingly prescribed as the panacea for life’s inevitable crises and challenges. 17 million schoolchildren worldwide have now been diagnosed with so-called mental disorders and prescribed cocaine-like stimulants and powerful antidepressants as treatments.

Teen suicides have tripled since 1960 in the United States. Today, suicide is the second leading cause of death (after car accidents) for 15 to 24 year-olds. Since the early 1990s, millions of children around the world have taken prescribed antidepressants that U.K. and U.S. authorities have now branded as suicidal agents. In September 2004, a U.S. Congressional hearing into these drugs found that not only do studies show the drugs are ineffective in children; they can drive them to suicidal behavior and hostility.

Psychiatrists are still telling governments that they can deliver the world from delinquency at a huge cost. Psychiatry remains long on promise and short in fact empty on delivery.

Support legislative measures that will protect children from psychiatric interference. Write your legislators about this. In Missouri find your legislators here.

Rexulti Fails to Get Results

REXULTI (generic brexpiprazole) is a prescription psychiatric drug from Otsuka Pharmaceutical Company and Lundbeck pharmaceutical company. Although it failed Phase II clinical trials for attention-deficit hyperactivity disorder (ADHD), it was approved by the U.S. Food and Drug Administration (FDA) in 2015 as an atypical antipsychotic and prescribed for the fake “disease” schizophrenia.

Then in 2018 the FDA approved it to treat symptoms of depression when antidepressants alone do not relieve symptoms.

The cost for Rexulti oral tablet 0.25 mg is around $1,166 for a supply of 30 tablets. It has similarities to Abilify, and apparently it was developed to replace Abilify when that drug’s patent expired in 2014.

Brexpiprazole affects the levels of the neurotransmitters dopamine and serotonin in the brain. It is thought to reduce dopamine output when dopamine concentrations are high and increase dopamine output when dopamine concentrations are low. It also activates serotonin receptors to increase serotonin levels in a manner thought to reduce hallucinogenic effects, which is a problem with all drugs that mess with serotonin in the brain.

The metabolism of the drug — that is, the mechanism which eventually eliminates it from the body — is mediated by Cytochrome P450 enzymes; people who are known poor metabolizers, i.e. those with a genetic lack of these enzymes, should be instructed to take half the usual dose, although this is rarely done, since the patient must first be tested for this genetic condition. It is estimated that 10% of Caucasians and 7% of African Americans are Cytochrome P450 deficient. The consequences for someone with this deficiency who takes this drug are an increased risk for the accumulation of the non-metabolized drug in the body and the resultant increase in adverse side effects such as depression, violence and suicide.

Drugs like Rexulti can raise the risk of death in the elderly, and it is not approved for the treatment of patients with dementia-related psychosis. This drug may also increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. It is not approved for the treatment of people younger than 18 years of age.

Rexulti may cause other serious side effects, including: compulsive, uncontrollable behaviors such as gambling, shopping, binge eating and sex (the same as with Abilify); stroke in elderly people; Neuroleptic Malignant Syndrome; high fever; stiff muscles; confusion; sweating; changes in pulse, heart rate, or blood pressure; high blood sugar (hyperglycemia); weight gain; seizures; difficulty swallowing; uncontrolled body movements known as tardive dyskinesia. Tardive dyskinesia may not go away, even after one stops taking the drug, and tardive dyskinesia may also start some time after one stops taking the drug.

The real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful. All psychiatric treatments, not just psychiatric drugs, are dangerous. Find Out! Fight Back!